Metastatic Breast Cancer: New HER2 Imaging Test

We are studying a new imaging method using 68Ga-ABS011 to see how well it detects HER2 status in metastatic breast cancer and other solid tumors. This may help improve diagnosis and treatment management.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Gallium (68ga) Edotreotide
Gallium-68 edotreotide is a radiolabeled tracer used in PET scans to locate neuroendocrine tumors that have somatostatin receptors.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Onze-Lieve-Vrouwziekenhuis
Oncology
Aalst, Belgium
Chirec
Oncology
Etterbeek, Belgium
UZ Brussel
Oncology
Ganshoren, Belgium

Sponsor: Abscint
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.